1563192922473_5d0bb4ec1e7a830004e3728b_logo

1594079869255_5f0361708104f725c984f69d_logo

One World Pharma

1557146762349_5c6edef51a7afb0004fde5de_logo

1571094173876_5da4ed08e27e0a0004ce3b9e_logo

1584055867459_5e6ab9a4acd991000434a556_logo

American Heart Association logo

$20 million research initiative supports health equity in high blood pressure prevention

(NewMediaWire) - April 19, 2021 - DALLAS - The American Heart Association, the world’s leading voluntary organization dedicated to a world of longer, healthier lives, is investing $20 million to study ways to prevent high blood pressure, particularly in underrepresented populations. Applications are now being accepted for coordinated submission of three to five research centers and a coordinating center that will be funded through this fast-track initiative. Letters of intent are required and due by Friday, April 23, 2021. The Health Equity Research Network (HERN) on the Prevention of Hypertension is part of the multi-pronged approach of the American Heart Association’s unprecedented pledge to aggressively address social determinants while working to support and improve the equitable health of all communities. High blood pressure is one of the leading risk factors of heart disease and stroke and is also a health equity issue. Significant racial and ethnic disparities in both prevalence of hypertension and its management have been well documented. Uncontrolled hypertension is particularly acute in communities of color. As such, this research initiative provides a mechanism to advance the science of prevention of hypertension with a focus on health equity. According to the American Heart Association Heart Disease and Stroke Statistics – 2021 Update: Nearly half of all U.S. adults (47.3%, 121.5 million people age 20 or older) have high blood pressure. The prevalence of hypertension in Black people in the U.S. is among the highest in the world - 56.6% among males and 55.3% among females. Black adults are more likely (33.0%) to have been told on two or more occasions that they had hypertension than American Indian/Alaska Native adults (26.4%), white adults (23.5%), Hispanic or Latino adults (22.9%) or Asian adults (19.5%). The lifetime risk for high blood pressure is 86.1% for Black males, 85.7%  for Black females, 83.8% for white males and 69.3% for white females. Scientific research teams interested in applying for the new grants can get more information here. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.  ###  For Media Inquiries: Cathy Lewis, cathy.lewis@heart.org; (214) 706-1324 For Public Inquiries: 1-800-AHA-USA1 (242-8721) heart.org and stroke.org

Tauriga Sciences Inc. Introduces its Newest Product Line: The Tauri-Gum Summertime Collection

This Product Line is Comprised of Embroidered: Hiking Backpack (with accessories), Folding Beach Chair, and Insulated Can CoolerNEW YORK, NY - (NewMediaWire) - April 19, 2021 - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today introduced its newest product line: The Tauri-Gum™ Summertime Collection (“Summer Collection”).  This product line is beautifully embroidered and is comprised of: 1) Hiking Backpack (with accessories), 2) Folding Beach Chair, and 3) Insulated Can Cooler.  The Summer Collection will be available on the Company’s E-Commerce website (www.taurigum.com), starting in May 2021.The Company developed its “Summer Collection” product line to promote outdoor activities, during this upcoming summer.  Fun! Fitness! Sun! Safety! The Embroidered Hiking Backpack will come with several notable accessories: one Tauri-Gum™ Rainbow Pack, two Embroidered Face Masks, and two Embroidered Can Coolers.  The MSRP for the Hiking Backpack (with accessories): $149.99The Embroidered Folding Beach Chair will come with two Embroidered Can Coolers.  The MSRP is set at $64.99The Embroidered Insulated Can Coolers will be sold for: MSRP of $8.99 EachThe Embroidered Hiking BackpackABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.comComplementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.DISCLAIMER -- Forward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” ...

Neovasc Comments on EuroIntervention Article

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - April 19, 2021 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina.” The article, authored by Carlo Zivelonghi, M.D., Antwerp Cardiovascular Center, Antwerp, Belgium, describes objective improvements in effort tolerance and oxygen kinetics as assessed by cardiopulmonary exercise testing (CPET) in patients suffering from refractory angina treated with Neovasc Reducer™ (“Reducer”) implantation.In this multicenter prospective study, 37 patients with chronic refractory angina undergoing Reducer implantation were evaluated with CPET at baseline (before treatment) and at six-month follow-up after implantation of the device. The main endpoints of the analysis were improvements in VO2 max and in VO2 at anaerobic threshold (AT), measures which reflect cardiorespiratory fitness and endurance capacity in exercise performance. The results showed that Reducer treatment significantly improved cardiopulmonary parameters, reflected by improvement in VO2 max (+0.97 ml/kg/min [+11.3%], 12.2±3.6 ml/kg/min vs 13.2±3.7, p=0.026), and workload (+12.9 [+34%]; 68±28 W vs 81±49W, p=0.05). Angina severity reflected by the Canadian Cardiovascular Society (CCS) grading improved from a mean of 3.2±0.5 to 1.6±0.8, (p<0.01). Improvements in all Seattle Angina Questionnaire variables were also shown.“For the first time, we were able to demonstrate objective improvement in exercise capacity and oxygen kinetics during exercise,” said Dr. Maayan Konigstein, M.D., Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Israel. “VO2 max is an indicator of cardiorespiratory fitness, and the improved cardiopulmonary exercise capacity following treatment with Reducer is suggestive of improvement in myocardial ischemia and in exercise tolerance in these patients.”Fred Colen, President & Chief Executive Officer of Neovasc, added, “We congratulate the authors for their innovative work. We believe demonstrating objective evidence of improvement in oxygenated blood flow to the heart muscle and related objective outcomes, such as exercise ability and associated improved key cardiopulmonary parameters, provides further support for the improvement in overall clinical outcomes, as already indicated for patients receiving the Reducer. It is remarkable to see statistically significant improvements in these important cardiopulmonary parameters in such a small patient population.”Improvement in angina symptoms was observed in 32 patients (86.5%), with a mean improvement in CCS grade at follow up of 1.6±0.8. Only very limited differences in anti-anginal medications were recorded, with a mean of 1.9±1.1 drugs per patient at baseline vs 1.8±1.1 at follow-up (p=0.77). Prof. Stefan Verheye, M.D., PhD, Antwerp Cardiovascular Center Middelheim, Antwerp, Belgium, said, “It is reassuring to see the consistent improvements in chest pain in patients treated with the Reducer. The outcomes reported in this study build upon the literature supporting Reducer as an attractive option for patients suffering from refractory angina that are not candidates for traditional revascularization procedures.”About Reducer  The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides relief of angina symptoms by altering blood flow within the myocardium of the heart and increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is ...